{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:45:47Z","timestamp":1774125947861,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U54 GM104942"],"award-info":[{"award-number":["1U54 GM104942"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20 GM109098"],"award-info":[{"award-number":["P20 GM109098"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 GM103488"],"award-info":[{"award-number":["P30 GM103488"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["WV-INBRE P20 GM103434"],"award-info":[{"award-number":["WV-INBRE P20 GM103434"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.leukres.2018.08.002","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T12:19:19Z","timestamp":1533557959000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9950-5935","authenticated-orcid":false,"given":"Rajesh R.","family":"Nair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Piktel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner J.","family":"Geldenhuys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura F.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.leukres.2018.08.002_bib0005","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2018.08.002_bib0010","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1470-2045(08)70229-8","article-title":"Bone-marrow relapse in paediatric acute lymphoblastic leukaemia","volume":"9","author":"Bailey","year":"2008","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2018.08.002_bib0015","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3324\/haematol.2015.129692","article-title":"Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation","volume":"100","author":"Kunz","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2018.08.002_bib0020","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V83.3.758.758","article-title":"Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells","volume":"83","author":"Manabe","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.08.002_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/excr.1996.0201","article-title":"Molecular interactions between human B-cell progenitors and the bone marrow microenvironment","volume":"226","author":"Murti","year":"1996","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.leukres.2018.08.002_bib0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ccell.2016.11.002","article-title":"Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia","volume":"30","author":"Ebinger","year":"2016","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.leukres.2018.08.002_bib0035","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/leu.2012.306","article-title":"Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia","volume":"27","author":"Lutz","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2018.08.002_bib0040","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2009.011726","article-title":"Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia","volume":"95","author":"Wilson","year":"2010","journal-title":"Haematologica"},{"issue":"108","key":"10.1016\/j.leukres.2018.08.002_bib0045","doi-asserted-by":"crossref","DOI":"10.3791\/53645","article-title":"Modeling chemotherapy resistant leukemia in vitro","author":"Slone","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"17","key":"10.1016\/j.leukres.2018.08.002_bib0050","doi-asserted-by":"crossref","first-page":"23439","DOI":"10.18632\/oncotarget.8273","article-title":"BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy","volume":"7","author":"Slone","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.leukres.2018.08.002_bib0055","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/ni.2985","article-title":"Bcl-6 directly represses the gene program of the glycolysis pathway","volume":"15","author":"Oestreich","year":"2014","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.leukres.2018.08.002_bib0060","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1541-7786.MCR-15-0474","article-title":"Bone marrow microenvironment niche regulates miR-221\/222 in acute lymphoblastic leukemia","volume":"14","author":"Moses","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2018.08.002_bib0065","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/10611861003639796","article-title":"Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders","volume":"18","author":"Carroll","year":"2010","journal-title":"J. Drug Target."},{"issue":"48","key":"10.1016\/j.leukres.2018.08.002_bib0070","doi-asserted-by":"crossref","first-page":"78958","DOI":"10.18632\/oncotarget.12586","article-title":"Mitotic arrest-induced phosphorylation of Mcl-1 revisited using two-dimensional gel electrophoresis and phosphoproteomics: nine phosphorylation sites identified","volume":"7","author":"Chu","year":"2016","journal-title":"Oncotarget"},{"issue":"52","key":"10.1016\/j.leukres.2018.08.002_bib0075","doi-asserted-by":"crossref","first-page":"43359","DOI":"10.1074\/jbc.M112.423905","article-title":"The role of microtubules and their dynamics in cell migration","volume":"287","author":"Ganguly","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.leukres.2018.08.002_bib0080","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/leu.2016.192","article-title":"A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program","volume":"30","author":"Jones","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2018.08.002_bib0085","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2018.08.002_bib0090","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0041-008X(67)90048-8","article-title":"A toxicologic study of mithramycin","volume":"11","author":"Morrison","year":"1967","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.leukres.2018.08.002_bib0095","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/DDDT.S64940","article-title":"Preclinical profile of cabazitaxel","volume":"8","author":"Vrignaud","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"issue":"9","key":"10.1016\/j.leukres.2018.08.002_bib0100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrd3254","article-title":"Cabazitaxel","volume":"9","author":"Galsky","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"24","key":"10.1016\/j.leukres.2018.08.002_bib0105","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1093\/nar\/13.24.8695","article-title":"Investigations into the sequence-selective binding of mithramycin and related ligands to DNA","volume":"13","author":"Fox","year":"1985","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.leukres.2018.08.002_bib0110","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1097-0142(197304)31:4<889::AID-CNCR2820310419>3.0.CO;2-H","article-title":"Mithramycin in the treatment of metastatic Ewing\u2019s sarcoma","volume":"31","author":"Kofman","year":"1973","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2018.08.002_bib0115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mpo.2950240511","article-title":"Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin)","volume":"24","author":"Kennedy","year":"1995","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.leukres.2018.08.002_bib0120","first-page":"18","article-title":"Mithramycin-human toxicology and preliminary therapeutic investigation","volume":"8","author":"Curreri","year":"1960","journal-title":"Cancer Chemother. Rep."},{"issue":"1","key":"10.1016\/j.leukres.2018.08.002_bib0125","first-page":"36","article-title":"Mithramycin inhibition of ribonucleic acid synthesis","volume":"26","author":"Yarbro","year":"1966","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.leukres.2018.08.002_bib0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccr.2014.05.005","article-title":"Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma","volume":"26","author":"Vanner","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.leukres.2018.08.002_bib0135","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.celrep.2016.12.064","article-title":"Oncogenes activate an autonomous transcriptional regulatory circuit that drives glioblastoma","volume":"18","author":"Singh","year":"2017","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.leukres.2018.08.002_bib0140","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-12-3146","article-title":"Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors","volume":"19","author":"Vrignaud","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2018.08.002_bib0145","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2018.08.002_bib0150","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A multicenter phase II study of XRP6258 administered as a 1-h i.v. Infusion every 3 weeks in taxane-resistant metastatic breast cancer patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann. Oncol."},{"issue":"9747","key":"10.1016\/j.leukres.2018.08.002_bib0155","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.leukres.2018.08.002_bib0160","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2012-06-440230","article-title":"Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia","volume":"122","author":"Koss","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2018.08.002_bib0165","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3324\/haematol.2013.093823","article-title":"The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance","volume":"98","author":"Aries","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2018.08.002_bib0170","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood-2009-02-205963","article-title":"Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia","volume":"115","author":"Stam","year":"2010","journal-title":"Blood"},{"issue":"7336","key":"10.1016\/j.leukres.2018.08.002_bib0175","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature09779","article-title":"Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7","volume":"471","author":"Wertz","year":"2011","journal-title":"Nature"},{"issue":"5909","key":"10.1016\/j.leukres.2018.08.002_bib0180","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1126\/science.1164390","article-title":"Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells","volume":"322","author":"Colmone","year":"2008","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.leukres.2018.08.002_bib0185","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2141.2000.02157.x","article-title":"Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia","volume":"110","author":"Mohle","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2018.08.002_bib0190","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ccr.2014.04.015","article-title":"Leukemia propagating cells rebuild an evolving niche in response to therapy","volume":"25","author":"Duan","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.leukres.2018.08.002_bib0195","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2011-0364","article-title":"The European Medicines Agency review of cabazitaxel (Jevtana(R)) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use","volume":"17","author":"Pean","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.leukres.2018.08.002_bib0200","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00689589","article-title":"Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia","volume":"25","author":"Archimbaud","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.leukres.2018.08.002_bib0205","first-page":"697","article-title":"Observations on the mechanism of hemorrhagic toxicity in mithramycin (NSC 24559) therapy","volume":"29","author":"Monto","year":"1969","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.leukres.2018.08.002_bib0210","first-page":"1379","article-title":"Hepatic toxicity of low doses of mithramycin in hypercalcemia","volume":"68","author":"Green","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.leukres.2018.08.002_bib0215","doi-asserted-by":"crossref","first-page":"10881","DOI":"10.1038\/srep10881","article-title":"A new approach to reduce toxicities and to improve bioavailabilities of platinum-containing anti-cancer nanodrugs","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.leukres.2018.08.002_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070072","article-title":"Evaluation of nanoparticle uptake in co-culture cancer models","volume":"8","author":"Costa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2018.08.002_bib0225","article-title":"PLGA-PEG nanoparticles for targeted delivery of the mTOR\/PI3kinase inhibitor dactolisib to inflamed endothelium","author":"Gholizadeh","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.leukres.2018.08.002_bib0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12645-013-0046-3","article-title":"Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer","volume":"4","author":"Aggarwal","year":"2013","journal-title":"Cancer Nanotechnol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:11Z","timestamp":1758934751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618301796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":46,"alternative-id":["S0145212618301796"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.08.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}